BG106682A - Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцини и използването им като лекарствени средства - Google Patents

Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцини и използването им като лекарствени средства Download PDF

Info

Publication number
BG106682A
BG106682A BG106682A BG10668202A BG106682A BG 106682 A BG106682 A BG 106682A BG 106682 A BG106682 A BG 106682A BG 10668202 A BG10668202 A BG 10668202A BG 106682 A BG106682 A BG 106682A
Authority
BG
Bulgaria
Prior art keywords
compounds
methyl
general formula
hexahydro
alkyl
Prior art date
Application number
BG106682A
Other languages
Bulgarian (bg)
English (en)
Inventor
Adrian Carter
Helmut Ensinger
Wolfram Gaida
Matthias Grauert
Joachim Mierau
Thomas Weiser
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of BG106682A publication Critical patent/BG106682A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BG106682A 1999-11-27 2002-05-09 Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцини и използването им като лекарствени средства BG106682A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19957156A DE19957156A1 (de) 1999-11-27 1999-11-27 Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
PCT/EP2000/011585 WO2001051471A1 (de) 1999-11-27 2000-11-21 Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
BG106682A true BG106682A (bg) 2003-01-31

Family

ID=7930562

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106682A BG106682A (bg) 1999-11-27 2002-05-09 Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцини и използването им като лекарствени средства

Country Status (32)

Country Link
EP (1) EP1235809B1 (pl)
JP (1) JP2003519687A (pl)
KR (1) KR20020058042A (pl)
CN (1) CN1177825C (pl)
AR (1) AR026586A1 (pl)
AT (1) ATE254108T1 (pl)
AU (1) AU5789701A (pl)
BG (1) BG106682A (pl)
BR (1) BR0015786A (pl)
CA (1) CA2383114C (pl)
CO (1) CO5251469A1 (pl)
CZ (1) CZ20022120A3 (pl)
DE (2) DE19957156A1 (pl)
DK (1) DK1235809T3 (pl)
EA (1) EA005681B1 (pl)
EE (1) EE200200267A (pl)
ES (1) ES2210036T3 (pl)
HR (1) HRP20020460A2 (pl)
HU (1) HUP0204169A3 (pl)
IL (1) IL149607A0 (pl)
MX (1) MXPA02003822A (pl)
NO (1) NO20022457D0 (pl)
NZ (1) NZ519758A (pl)
PL (1) PL355493A1 (pl)
PT (1) PT1235809E (pl)
SK (1) SK9302002A3 (pl)
TR (1) TR200302031T4 (pl)
UA (1) UA72566C2 (pl)
UY (1) UY26448A1 (pl)
WO (1) WO2001051471A1 (pl)
YU (1) YU37902A (pl)
ZA (1) ZA200204056B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683089B2 (en) 2002-02-02 2004-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
DE10204276A1 (de) * 2002-02-02 2003-08-07 Boehringer Ingelheim Pharma N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
US10138207B2 (en) * 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121821A1 (de) * 1991-07-02 1993-01-14 Boehringer Ingelheim Kg Neue benzomorphane und ihre verwendung als arzneimittel
US5354758A (en) * 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19907874A1 (de) * 1999-02-23 2000-08-24 Boehringer Ingelheim Pharma N-(5-Phenyl-tetrahydrofuranyl)methyl- und N-(6-Phenyl-tetrahydropyranyl)methyl substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
UY26448A1 (es) 2001-06-29
ES2210036T3 (es) 2004-07-01
HUP0204169A3 (en) 2005-03-29
CA2383114A1 (en) 2001-07-19
PT1235809E (pt) 2004-04-30
AR026586A1 (es) 2003-02-19
ZA200204056B (en) 2003-07-30
HK1052176A1 (en) 2003-09-05
HUP0204169A2 (hu) 2003-03-28
EP1235809A1 (de) 2002-09-04
DK1235809T3 (da) 2004-03-15
BR0015786A (pt) 2002-08-13
HRP20020460A2 (en) 2003-10-31
NZ519758A (en) 2004-05-28
CN1177825C (zh) 2004-12-01
EA200200491A1 (ru) 2002-12-26
YU37902A (sh) 2005-07-19
ATE254108T1 (de) 2003-11-15
TR200302031T4 (tr) 2004-01-21
NO20022457L (no) 2002-05-24
UA72566C2 (uk) 2005-03-15
CN1399630A (zh) 2003-02-26
NO20022457D0 (no) 2002-05-24
WO2001051471A1 (de) 2001-07-19
CA2383114C (en) 2008-06-17
CZ20022120A3 (cs) 2002-09-11
IL149607A0 (en) 2002-11-10
EP1235809B1 (de) 2003-11-12
DE50004455D1 (de) 2003-12-18
EE200200267A (et) 2003-06-16
MXPA02003822A (es) 2002-12-13
AU5789701A (en) 2001-07-24
DE19957156A1 (de) 2001-05-31
PL355493A1 (pl) 2004-05-04
EA005681B1 (ru) 2005-04-28
SK9302002A3 (en) 2002-11-06
KR20020058042A (ko) 2002-07-12
JP2003519687A (ja) 2003-06-24
CO5251469A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
EP0170213B1 (en) Glutarimide antianxiety and antihypertensive agents
KR102337149B1 (ko) 인돌 및 피롤의 유도체, 이의 제조 방법 및 이를 함유하는 약제 조성물
JP2002529464A (ja) Ｙ５受容体拮抗薬としてのスピロインドリン類
CZ300754B6 (cs) Arylsulfonamidy a jejich analogy, zpusob jejich výroby, meziprodukty pro jejich výrobu, farmaceutické prostredky tyto látky obsahující a jejich použití
EP0162695B1 (en) 6-oxygenated-1,3,,4,5-tetrahydrobenz(cd)indol-4-amines
US5968949A (en) Substituted hydroisoquinoline derivatives and their use as pharmaceuticals
IL108247A (en) Pharmaceutical compositions containing dextrorotatory o-aryl ethers of morphinans for reducing adverse effects of neurotoxic injury, certain such novel compounds and their preparation
JP2003508528A (ja) ヘテロアリールオキシプロパノールアミン、その製造方法及びそれらを含有する医薬組成物
BG104607A (bg) Заместени изохинолинови производни и използванетоим като антиконвулсанти
CA2383114C (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions
KR20010024766A (ko) 1,4-디아자시클로헵탄 유도체
WO1990001025A1 (en) Enamine quaternary compounds, methods of making and their use as muscle relaxants
US6387921B1 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions
KR20010072262A (ko) 삼환식 카르복스아미드
EP1084122B1 (en) Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
JP5009785B2 (ja) ウレア誘導体、それを含有する医薬組成物およびそれらの医薬用途
JPH09508917A (ja) フェニルピロール誘導体およびそのドーパミンｄ▲下３▼アンタゴニストとしての使用
CZ303194A3 (en) 1-(phenylalkylaminoalkyloxy)-5-phenylpyrazole compounds as well as a process and intermediates for their preparation
CA1266675A (en) 6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines
EA003370B1 (ru) Новые 2,3,3a,4,9,9a-гексагидро-8-гидрокси-1h-бенз[f]индолы, способ их получения и их применение в качестве лекарственных средств
PL149869B1 (pl) Sposób wytwarzania pochodnych morfinanu